Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Genomics
71%
T Cell
58%
KRAS
52%
Tumor Progression
50%
Oxidative Phosphorylation
44%
Reprogramming
43%
Immunity
39%
Immune Checkpoints
38%
Mouse Model
35%
Mesenchymal-Epithelial Transition
35%
PD-L1
34%
Myeloid
33%
P53
29%
CD8
29%
Drug Resistance
29%
Oncogene
24%
Transcriptomics
23%
Genetics
23%
Epidermal Growth Factor Receptor
23%
Phosphotransferase
23%
Kinase
23%
Programmed Cell Death
21%
Mir-200
19%
Upregulation
19%
Stem Cell
18%
CTLA-4
17%
Radiosensitivity
17%
Gene Expression
16%
DNA Repair
16%
Functional Genomics
15%
Small Molecule
15%
Cancer Model
15%
Epigenetics
15%
Dynamics
14%
Wart Virus
14%
SMARCB1
14%
Receptor Tyrosine Kinase
13%
CRISPR
13%
Methyltransferase
13%
MEK Inhibitor
13%
Tumor-Infiltrating Lymphocytes
13%
Enhancer Region
12%
Chromosome Instability
12%
Cell Invasion
12%
Small Hairpin RNA
12%
Carcinogenesis
12%
Pan-cancer
12%
Transcriptome
12%
Cell Cycle
12%
Myc
12%
extracellular signal regulated kinase
11%
DNA Methylation
11%
Whole Genome Sequencing
11%
ZEB1
11%
Tyrosine Phosphorylation
11%
Unfolded Protein Response
11%
Arginine
11%
Telomere
11%
Signaling Protein
11%
Integrin
11%
RNA Sequence
10%
Endoplasmic Reticulum Stress
10%
Cell Growth
10%
Gene Expression Profiling
10%
Homeostasis
9%
Mitochondrion
9%
Evolution
9%
Drug Targeting
9%
Histone H3
9%
Interferon
9%
Protein Homeostasis
9%
MAPK Signaling
9%
Cell Death
9%
Metabolic Pathway
9%
Exome Sequencing
9%
Transcription Factor
8%
Phosphatase
8%
Cell Infiltration
8%
Genetic Divergence
8%
Genome Sequencing
8%
Cell Fate
8%
Mammalian Target of Rapamycin
8%
Cytokine
8%
Drive
8%
Transcription Factor ZEB1
8%
Lysine
8%
YAP1
7%
Gene Function
7%
Cell Migration
7%
Genome Instability
7%
SWI/SNF
7%
Cytotoxic T Cell
7%
Fibroblast
7%
GTPase-activating Protein
7%
Lipid Peroxidation
7%
Tumor Suppressor Protein
7%
Lipid
6%
Essential Gene
6%
Cadherin
6%
Medicine and Dentistry
Neoplasm
88%
Pancreas Cancer
57%
Pancreas Adenocarcinoma
45%
Immunity
38%
Cancer Cell
37%
Malignant Neoplasm
36%
Metastatic Carcinoma
29%
Triple Negative Breast Cancer
28%
Cancer
26%
T Cell
25%
Targeted Therapy
25%
Tumor Progression
24%
Oxidative Phosphorylation
24%
Melanoma
21%
In Vitro
20%
Immunotherapy
20%
Cytotoxic T-Cell
19%
Tumor Cell
18%
Xenograft
18%
Ganglioglioma
18%
Immune Checkpoint Blockade
18%
Lung Cancer
18%
Ovarian Cancer
17%
Mesenchymal-Epithelial Transition
17%
Diseases
17%
Programmed Death-Ligand 1
16%
Programmed Cell Death
14%
Immunosuppressive Treatment
14%
Protein P53
14%
MEK Inhibitor
14%
DNA Damage Response
13%
Myeloid-Derived Suppressor Cell
13%
Functional Genomics
13%
Non-Small Cell Lung Cancer
12%
Bispecific Antibody
12%
Drug Resistance
12%
Biological Marker
12%
DNA Repair
11%
Breast Cancer
11%
Tumor Regression
11%
Epidermal Growth Factor Receptor
11%
Androgen Receptor
11%
Interferon
11%
Glioblastoma
11%
Protein Phosphorylation
11%
Colorectal Carcinoma
11%
Receptor Blocking
11%
Radiosensitivity
11%
Integrin
11%
Cancer Model
10%
Immunosuppressive Drug
10%
CTLA-4
9%
Antineoplastic Activity
9%
Oncology
9%
Cell Line
9%
PARP Inhibitor
9%
Interleukin 8 Receptor, Beta
9%
Monotherapy
8%
Tumor Xenograft
8%
extracellular signal regulated kinase
8%
Cellular Infiltration
8%
Clinical Trial
8%
Therapy Resistance
7%
Lung Tumor
7%
Primary Tumor
7%
Myeloid Cell
7%
microRNA 200
7%
Memory T Cell
7%
Tumor Model
7%
Somatics
7%
Clustered Regularly Interspaced Short Palindromic Repeat
7%
Cytotoxic Chemotherapy
7%
Transcriptomics
6%
Neoadjuvant Chemotherapy
6%
Stem Cell
6%
CDK4/6 Inhibitor
6%
Pancreatic Ductal Adenocarcinoma
6%
Combination Therapy
6%
Cancer Growth
6%
Cell Invasion
6%
Cell Differentiation
6%
Cell Signaling Pathway
6%
Upregulation
6%
Prostate Cancer
6%
Gene Expression
6%
Lung Adenocarcinoma
6%
Gene Expression Profiling
6%
Metabolism
6%
Mammalian Target of Rapamycin
5%
Gene Fusion
5%
Ganglioneuroblastoma
5%
Notch
5%
Talazoparib
5%
Fibroblast Growth Factor Receptor 2
5%
Protein Homeostasis
5%
Olaparib
5%
Spindle Checkpoint
5%
RNA Metabolism
5%
Division
5%
Mantle Cell Lymphoma
5%
Keyphrases
Tumor
52%
Pancreatic Cancer
43%
Pancreatic Ductal Adenocarcinoma
34%
Oxidative Phosphorylation (OXPHOS)
34%
Tumor Cells
32%
Lung Cancer
31%
Targeted Therapy
25%
MEK Inhibitor (MEKi)
24%
Programmed Death-ligand 1 (PD-L1)
23%
Metastasis
22%
Non-small Cell Lung Cancer (NSCLC)
22%
Triple-negative Breast Cancer
20%
Cancer Cells
19%
Patient-derived Xenograft
18%
Epithelial-to-mesenchymal Transition
18%
Tumor Growth
17%
Immunosuppression
17%
PD-1 Blockade
16%
Melanoma
15%
Tumor Microenvironment
15%
T Cells
15%
IACS-010759
14%
Dual Inhibition
13%
Copy number Variation
13%
Resistance Mechanisms
13%
Cyclin-dependent Kinase 4 (CDK4)
13%
Glioma
13%
Zinc Finger E-box Binding Homeobox 1 (ZEB1)
13%
Metabolic Reprogramming
12%
SWItch/Sucrose Non-fermentable
12%
P53 mutant
12%
Bispecific Antibody
12%
Durable Response
12%
Mitogen-activated Protein Kinase
11%
Structural Variants
11%
Enhancer Reprogramming
11%
Androgen Receptor Blockade
11%
Pan-cancer
11%
Molecular Characterization
11%
4-1BB
11%
SMARCB1
11%
Mouse Model
11%
Gene Expression
11%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
10%
Tumor Progression
9%
Yes-associated Protein 1 (YAP1)
9%
Non-cell Autonomous
9%
Apoptosis
9%
Primary Tumor
9%
Structural Variation
9%
Acute Myeloid Leukemia
9%
Tumor Regression
9%
Therapeutic Target
9%
CXCR2
9%
Tumor-infiltrating Lymphocytes
9%
Tumor Immunity
8%
Pancreatic Cancer Cells
8%
Lung Cancer Cells
8%
Colorectal Cancer
8%
Unfolded Protein Response
8%
PI3K-AKT-mTOR Pathway
8%
Expression Subtypes
8%
Single-cell RNA Sequencing (scRNA-seq)
8%
Tumor-infiltrating T Cells
8%
Human Cancer
8%
PD-L1 Expression
8%
Radiation Therapy
8%
DNA Damage Response
8%
Monotherapy
8%
Myeloid-derived Suppressor Cells
8%
MiR-200
8%
Lung Adenocarcinoma
8%
Pten
7%
Adoptive Cell Therapy
7%
Pancreatic Tumor
7%
Chemotherapy Resistance
7%
Oncogene
7%
Proteostasis
7%
Cytotoxic T Cells
7%
PIK3CA
7%
CD8+
7%
Genome Rearrangement
7%
Immune Checkpoint Therapy
7%
Short Hairpin RNA (shRNA)
7%
Small Molecule Inhibitors
7%
Cell Death
7%
Immunosuppressive Microenvironment
7%
Advanced Solid Tumors
7%
DNA Repair
6%
Palbociclib
6%
Therapy Resistance
6%
Chromatin State
6%
Pharmacologic
6%
Myelodysplastic Syndrome
6%
Microenvironment
6%
Renal Medullary Carcinoma
6%
DNA Damage
6%
Clinically Significant
6%
Redox Balance
6%
Phase II Clinical Trial
6%